The heterogeneity of ovarian cancer requires biomarkers for personalized medicine. DNA methylation aberration is a hallmark of cancer. The attempt of using DNA methylation as biomarkers for prognosis prediction is appealing. Methylomic analysis using next generation sequencing technology has never been applied in ovarian cancer research. The present study for the first time is to explore the methylomics of ovarian cancer using this cutting edge technology.
|Original language||Chinese (Traditional)|
|Number of pages||1|
|Journal||Biomarkers and Genomic Medicine|
|Publication status||Published - Sept 2013|